This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0003319708321668v1 59/2_suppl/62S    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Efthimiadis, A. Search for Related Content PubMed PubMed Citation Articles by Efthimiadis, A. Social Bookmarking                         What's this?

Rosuvastatin and Cardiovascular Disease: Did the Strongest Statin Hold the Initial Promises?

Aristotle's University of Thessaloniki

^* To whom correspondence should be addressed. E-mail: a_efthimiadis{at}hotmail.com.

	Abstract

Rosuvastatin is the latest and most potent statin currently on the market. It has the greatest efficacy compared with all other available statins on total cholesterol and low-density lipoprotein cholesterol (LDLC) reduction, and also provides a significant increase in high-density lipoprotein cholesterol (HDL-C) better than atorvastatin. Imaging studies showed a regression of atheroma in secondary prevention patients using an intravascular ultrasound technique and a hold of progression in primary prevention patients using carotid intima–media thickness as a surrogate marker. The JUPITER trial, a primary prevention large-scale, prospective study to examine the role of statin therapy in individuals with raised C-reactive protein but normal LDL-C levels, was recently terminated early due to a significant reduction of events in the rosuvastatin group. Rosuvastatin has held its initial promises as a very potent statin, with favourable effects on HDL, showing a regression or a halt of the atherosclerotic burden and reducing cardiovascular events in low-risk patients.

First published on July 15, 2008, doi:10.1177/0003319708321668

Angiology 2008;59:62S.

A more recent version of this article appeared on August 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. I. Paraskevas, C. Psathas, T. Dragios, D. G. Chatzis, D. P. Mikhailidis, and Z. S. Kyriakides The Impact of Novel Treatment Modalities on the Therapeutic Approach of Cardiovascular Diseases Angiology, February 1, 2009; 60(1): 5 - 7. [PDF]

				K. I. Paraskevas, N. Bessias, T. T. Papas, V. Andrikopoulos, and D. P. Mikhailidis Is High-sensitivity C-reactive Protein Associated With Subclinical Peripheral Atherosclerosis? Angiology, February 1, 2009; 60(1): 8 - 11. [PDF]